August 8, 2022 News by Marisa Wexler, MS Study Shares Successful Recruitment Strategies for MS Exercise Trial By engaging a variety of stakeholders from across the multiple sclerosis (MS) community, researchers in the U.S. Deep South were able to enroll more than 800 patients to a clinical trial in just over two years in what’s considered the largest study of an exercise intervention in MS patients…
January 17, 2022 News by Marta Figueiredo, PhD 1st RRMS Patient Enrolled in ENSURE-2 Trial of Oral IMU-838 The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…
December 11, 2020 News by Joana Carvalho, PhD MS Patients Urged to Enroll in Clinical Trial Assessing Chronic Fatigue Treatments Adults with multiple sclerosis (MS) are being urged to enroll in a new clinical trial — now recruiting in Washington and Michigan states — that aims to assess the effectiveness of different treatments to counteract the effects of chronic fatigue. The investigators are hopeful that data from this…
October 30, 2019 News by Alice Melão, MSc First Relapsing MS Patient Enrolled in Phase 3 Trial of Mapi Pharma’s Once-monthly Glatiramer Formulation A new Phase 3 clinical trial to explore the safety and efficacy of Mapi Pharma’s once-a-month injectable formulation of glatiramer acetate — named GA Depot — has started enrolling patients with relapsing multiple sclerosis (MS). The trial (NCT04121221) is expected to enroll approximately 960 participants, 18 to 55…
June 13, 2019 News by Alice Melão, MSc DELIVER-MS Trial Recruiting RRMS Patients to Help Improve Treatment Decision-making A clinical trial based at the Cleveland Clinic and the University of Nottingham, U.K., is recruiting patients with relapsing-remitting multiple sclerosis (RRMS) to compare two treatment strategies, the National Multiple Sclerosis Society announced. The Phase 4 study, called DELIVER-MS (NCT03535298), intends to enroll about 800…
March 22, 2019 News by Jose Marques Lopes, PhD Phase 3 Trial of ADS-5102 Recruiting Participants of All MS Types A Phase 3 trial testing ADS-5102 (amantadine) extended release capsules in all types of multiple sclerosis (MS) is enrolling participants to determine whether the oral therapy can improve walking speed. A total of 570 adults with MS, ages 18 to 70 years, who have difficulty walking will be…
February 19, 2019 News by Santiago Gisler Participants Sought for Clinical Trial Studying Effects of Lipoic Acid on Progressive MS A clinical trial to test the effects of antioxidant treatment with lipoic acid on progressive forms of multiple sclerosis (MS) is recruiting 118 participants at seven sites in North America. The study sites include: Birmingham, Alabama; Burlington, Vermont; Portland, Oregon; Salt Lake City, Utah; Seattle, Washington; Washington, D.C., and;…
January 7, 2019 News by Alice Melão, MSc More Effort Needed to Recruit Minorities to Phase 3 Clinical Trials, MS Expert Says Because multiple sclerosis (MS) presentation and progression course can be very different between people of African ancestry and Caucasians, the recruitment of minorities to Phase 3 clinical trials is of particular importance. Researchers in the MS field and the general MS community should make a greater effort to improve…
September 20, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – GeNeuro Reaches Enrollment Halfway Mark in Study of GNbAC1 to Treat Multiple Sclerosis GeNeuro announced that it has reached — more quickly than expected — the halfway mark for patient enrollment in its Phase 2b study, CHANGE-MS, assessing GNbAC1 as a therapy for relapsing-remitting multiple sclerosis (RRMS). Patient recruitment is continuing at sites across Europe. The company also reported on the trial’s design in a poster presentation, “A placebo…
